Clinical Trials Logo

Cardiovascular Outcomes clinical trials

View clinical trials related to Cardiovascular Outcomes.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT03899675 Completed - Clinical trials for Autonomic Nervous System

Impact of Caffeine Intake on Autonomic Parameters in the Exercise of Strength

Start date: December 19, 2018
Phase: N/A
Study type: Interventional

The objective of this study was to evaluate the variability of the heart rate of exercise physicists with and without caffeine intake. Practitioners of resisted physical exercise, specifically bodybuilding, who are young adults between the ages of 18 and 30 will participate in the study. To define the sample size, a sample calculation was performed based considering as variable the RMSSD index (square root of the square mean of the differences between the adjacent normal iRRs). The significant difference magnitude assumed was 12 ms, considering a standard deviation of 16.2 ms, with alpha risk of 5% and beta of 80%. A minimum of 14 subjects per group were required in the survey. A total of 32 subjects will participate in the research, being these divided and allocated in different groups. Sampling will be of the intentional kind.

NCT ID: NCT02601352 Completed - Clinical trials for Cardiovascular Outcomes

Air Pollution and Cardiometabolic Study

Start date: September 2015
Phase:
Study type: Observational

The study mainly focuse on examining the subjects living in traffic polluted area and assessing the popuation health risk using disease and risk assessment models.

NCT ID: NCT01921010 Completed - Clinical trials for Cardiovascular Outcomes

Benefit of Elevation of HDL-C in Women

Start date: June 2003
Phase: Phase 4
Study type: Interventional

The combination of HDL-C elevation, lowering of triglycerides and further LDL-C reduction accomplished by the addition of niacin to statin medication would improve endothelial function as compared to LDL-C reduction alone in patients with and without coronary artery disease and the combination of low HDL-C/high triglycerides. The combination of lipid lowering therapy would have beneficial effects on markers of inflammation. These benefits would be particularly evident in women.